OCGN
Ocugen
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Ocugen and Roots Pharmaceutical complete a licensing agreement for OCU400 gene-modifier therapy for retinitis pigmentosa across the Middle East and North AfricaOct 14, 2026
- Ocugen receives provisional approval and Priority Designation in the Bahamas to provide OCU400 for retinitis pigmentosa under the Longevity and Regenerative Therapies ActSep 25, 2026
- Ocugen receives FDA RMAT designation for OCU410 in geographic atrophy secondary to dry AMDJul 29, 2026
- Ocugen completed dosing early in its Phase 2/3 pivotal trial of OCU410ST for Stargardt diseaseApr 1, 2026
- Ocugen reported 12-month Phase 2 ArMaDa topline data for OCU410 gene therapy in geographic atrophyMar 24, 2026